A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

Back to Search
Print
Bookmark Trial

NCT00159874

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Palo Alto, California, 34304, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pulmonary Arterial Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
1-17 year
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients must complete the 16 Week double-blind efficacy study A1481131.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Any patient who did not complete Study A1481131.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Pulmonary Arterial HypertensionPatient Reported Outcomes in Pulmonary Arterial Hypertension NCT01792622
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Pulmonary Arterial HypertensionOpen Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study NCT00878943
  1. Hyderabad, Andra Pradesh
  2. Ahmedabad, Gujarat
  3. Vadodara, Gujarat
  4. Bangalore, Karnataka
  5. Noida, Uttar Pradesh
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Pulmonary Arterial HypertensionAssess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension NCT00323297
  1. Los Angeles, California
  2. Detroit, Michigan
  3. Pittsburgh, Pennsylvania
  4. Houston, Texas
  5. Houston, Texas
  6. San Antonio, Texas
  7. Darlinghurst, New South Wales
  8. Chermside, Queensland
  9. Praha 2,
  10. Praha 4,
  11. Lille,
  12. Lille,
  13. Vandoeuvre Les Nancy,
  14. Berlin,
  15. Coburg,
  16. Essen,
  17. Giessen,
  18. Hannover,
  19. Homburg,
  20. Leipzig,
  21. Muenchen,
  22. Nuernberg,
  23. Wuerzburg,
  24. Haidari, Athens
  25. Haifa,
  26. Petach Tikva,
  27. Napoli,
  28. Roma,
  29. Taipei,
  30. Papworth Everard, Cambridgeshire
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Pulmonary Arterial HypertensionTo Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension. NCT00430716
  1. Phoenix, Arizona
  2. Augusta, Georgia
  3. Decatur, Georgia
  4. Elk Grove Village, Illinois
  5. Indianapolis, Indiana
  6. Chapel Hill, North Carolina
  7. Charlotte, North Carolina
  8. Houston, Texas
  9. Salt Lake City, Utah
  10. Richmond, Virginia
  11. Richmond, Virginia
  12. Leuven,
  13. Porto Alegre, RS
  14. Sao Paulo, SP
  15. Sofia,
  16. Sofia,
  17. Beijing,
  18. Shanghai,
  19. Haidari, Athens
  20. Hyderabad, Andhra Pradesh
  21. Ahmedabad, Gujarat
  22. Vadodara, Gujarat
  23. Bangalore, Karnataka
  24. Noida, Uttar Pradesh
  25. Pavia,
  26. Roma,
  27. Riga,
  28. Kuala Lumpur,
  29. Amsterdam,
  30. Rotterdam,
  31. Manila City,
  32. Quezon City,
  33. Krakow,
  34. Zabrze,
  35. Timisoara, Timis
  36. Iasi,
  37. Moscow,
  38. Moscow,
  39. Amphoe Mueang, Khon Kaen
  40. Bangkok,
  41. Norwich, Norfolk
  42. Newcastle Upon Tyne, Tyne and Wear
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
Official Title  ICMJE A Multicenter, Long-Term Extension Study to Assess Safety of Oral Sildenafil Citrate In The Treatment Of Subjects Who Have Completed Study A1481131
Brief Summary Active treatment, dose-blinded extension study evaluating the safety and long term efficacy of sildenafil citrate in children with PAH.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Pulmonary Arterial Hypertension
Intervention  ICMJE
  • Drug: Sildenafil citrate
    Oral, subjects with body weight ?8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight >20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight >45 kg: 80 mg 3 times a day (tid)
  • Drug: Sildenafil citrate
    Oral,10 mg 3 times a day (tid), only subjects with body weight >20 kg
  • Drug: Sildenafil citrate
    Oral, subjects with body weight ?8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight >20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight >45 kg: 40 mg 3 times a day (tid)
Study Arms  ICMJE
  • Experimental: Sildenafil high dose
    As per Protocol Amendment 8 (Aug 2011), all doses in the high dose treatment group were discontinued. Subjects who were receiving these doses and continued in the study were requested to down titrate.
    Intervention: Drug: Sildenafil citrate
  • Experimental: Sildenafil Low dose
    Intervention: Drug: Sildenafil citrate
  • Experimental: Sildenafil medium dose
    As per Protocol Amendment 8 (August 2011), the dose 40 mg TID in the medium dose treatment group was discontinued. Subjects who were receiving this dose and continued in the study were requested to down titrate.
    Intervention: Drug: Sildenafil citrate
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 17, 2014)		234
Original Enrollment  ICMJE
 (submitted: September 8, 2005)		204
Actual Study Completion Date  ICMJE December 2012
Actual Primary Completion Date December 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients must complete the 16 Week double-blind efficacy study A1481131.

Exclusion Criteria:

  • Any patient who did not complete Study A1481131.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 1 Year to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Brazil,   Chile,   Colombia,   Guatemala,   Hungary,   India,   Italy,   Japan,   Malaysia,   Mexico,   Poland,   Russian Federation,   Sweden,   Taiwan,   United States
Removed Location Countries Canada,   Costa Rica,   Panama,   Singapore
 
Administrative Information
NCT Number  ICMJE NCT00159874
Other Study ID Numbers  ICMJE A1481156
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP